Refinement of Mouse Protocols for the Study of Platelet Thromboembolic Responses In Vivo

Abstract

Mouse models of thromboembolism are frequently used to investigate platelet function in vivo and, according to European Union (EU) legislation, must be conducted in the context of replacement, refinement and reduction. We have previously developed a refined real-time mouse model of thromboembolism as an alternative to models of thromboembolic mortality which inflict considerable pain and suffering. Real-time monitoring involves infusion of radiolabelled platelets into the circulation of anaesthetized mice, and platelet aggregation is measured as increases in platelet-associated counts in the pulmonary vasculature following injection of platelet agonists. This gives a definitive data set on the tissue localization and extent of platelet activation. We developed an additional, more simplistic alternative to mortality models based on blood microsampling which entails the measurement of circulating platelet counts following agonist stimulation. Blood microsamples were collected from the tail vein of anaesthetized mice at three different time points leading to a reduction in animal numbers. Platelet counts significantly dropped 1 minute after stimulation with collagen or thrombin and were restored over 10 minutes. These results correlate with those obtained via real-time monitoring and were confirmed by immunohistochemistry. Pre-treatment of mice with aspirin significantly inhibited the decrease in platelet counts following collagen. These data suggest that blood microsampling may be implemented as a simplistic refined alternative to mortality models of thromboembolism when specialized monitoring equipment, or use of radioactive isotopes for real-time monitoring, which remains the ‘gold standard’, is not feasible. Microsampling refines and reduces animal procedures in compliance with current EU legislation.

Keywords

mouse model - platelets - thromboembolism

• References

• 1 Gawaz M. Role of platelets in coronary thrombosis and reperfusion of ischemic myocardium. Cardiovasc Res 2004; 61 (03) 498-511
• 2 Russell JC, Proctor SD. Small animal models of cardiovascular disease: tools for the study of the roles of metabolic syndrome, dyslipidemia, and atherosclerosis. Cardiovasc Pathol 2006; 15 (06) 318-330
• 3 Nieswandt B, Aktas B, Moers A, Sachs UJ. Platelets in atherothrombosis: lessons from mouse models. J Thromb Haemost 2005; 3 (08) 1725-1736
• 4 Mizurini DM, Francischetti IM, Monteiro RQ. Aegyptin inhibits collagen-induced coagulation activation in vitro and thromboembolism in vivo. Biochem Biophys Res Commun 2013; 436 (02) 235-239
• 5 Momi S, Caracchini R, Falcinelli E, Evangelista S, Gresele P. Stimulation of platelet nitric oxide production by nebivolol prevents thrombosis. Arterioscler Thromb Vasc Biol 2014; 34 (04) 820-829
• 6 Ma D, Mizurini DM, Assumpção TC. , et al. Desmolaris, a novel factor XIa anticoagulant from the salivary gland of the vampire bat (Desmodus rotundus) inhibits inflammation and thrombosis in vivo. Blood 2013; 122 (25) 4094-4106
• 7 Emerson M. Refinement, reduction and replacement approaches to in vivo cardiovascular research. Br J Pharmacol 2010; 161 (04) 749-754
• 8 Tymvios C, Jones S, Moore C, Pitchford SC, Page CP, Emerson M. Real-time measurement of non-lethal platelet thromboembolic responses in the anaesthetized mouse. Thromb Haemost 2008; 99 (02) 435-440
• 9 May GR, Herd CM, Butler KD, Page CP. Radioisotopic model for investigating thromboembolism in the rabbit. J Pharmacol Methods 1990; 24 (01) 19-35
• 10 Solomon A, Smyth E, Mitha N. , et al. Induction of platelet aggregation after a direct physical interaction with diesel exhaust particles. J Thromb Haemost 2013; 11 (02) 325-334
• 11 Smyth E, Solomon A, Vydyanath A. , et al. Induction and enhancement of platelet aggregation in vitro and in vivo by model polystyrene nanoparticles. Nanotoxicology 2015; 9 (03) 356-364
• 12 Apostoli GL, Solomon A, Smallwood MJ, Winyard PG, Emerson M. Role of inorganic nitrate and nitrite in driving nitric oxide-cGMP-mediated inhibition of platelet aggregation in vitro and in vivo. J Thromb Haemost 2014; 12 (11) 1880-1889
• 13 Emerson M, Momi S, Paul W, Alberti PF, Page C, Gresele P. Endogenous nitric oxide acts as a natural antithrombotic agent in vivo by inhibiting platelet aggregation in the pulmonary vasculature. Thromb Haemost 1999; 81 (06) 961-966
• 14 Tymvios C, Moore C, Jones S, Solomon A, Sanz-Rosa D, Emerson M. Platelet aggregation responses are critically regulated in vivo by endogenous nitric oxide but not by endothelial nitric oxide synthase. Br J Pharmacol 2009; 158 (07) 1735-1742
• 15 Kilkenny C, Browne WJ, Cuthill IC, Emerson M, Altman DG. Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research. PLoS Biol 2010; 8 (06) e1000412
• 16 Bodary PF, Eitzman DT. Animal models of thrombosis. Curr Opin Hematol 2009; 16 (05) 342-346
• 17 Heeringa P, van Goor H, Itoh-Lindstrom Y. , et al. Lack of endothelial nitric oxide synthase aggravates murine accelerated anti-glomerular basement membrane glomerulonephritis. Am J Pathol 2000; 156 (03) 879-888
• 18 Iafrati MD, Vitseva O, Tanriverdi K. , et al. Compensatory mechanisms influence hemostasis in setting of eNOS deficiency. Am J Physiol Heart Circ Physiol 2005; 288 (04) H1627-H1632
• 19 Marjanovic JA, Li Z, Stojanovic A, Du X. Stimulatory roles of nitric-oxide synthase 3 and guanylyl cyclase in platelet activation. J Biol Chem 2005; 280 (45) 37430-37438
• 20 Ozüyaman B, Gödecke A, Küsters S, Kirchhoff E, Scharf RE, Schrader J. Endothelial nitric oxide synthase plays a minor role in inhibition of arterial thrombus formation. Thromb Haemost 2005; 93 (06) 1161-1167
• 21 Dayal S, Wilson KM, Leo L, Arning E, Bottiglieri T, Lentz SR. Enhanced susceptibility to arterial thrombosis in a murine model of hyperhomocysteinemia. Blood 2006; 108 (07) 2237-2243
• 22 Assafim M, Frattani FS, Ferreira MS, Silva DM, Monteiro RQ, Zingali RB. Exploiting the antithrombotic effect of the (pro)thrombin inhibitor bothrojaracin. Toxicon 2016; 119: 46-51
• 23 Choi JH, Kim SJ, Kim S. A novel anticoagulant protein with antithrombotic properties from the mosquito Culex pipiens pallens. Int J Biol Macromol 2016; 93: 156-166
• 24 Huang SW, Kuo HL, Hsu MT, Tseng YJ, Lin SW, Kuo SC, Peng HC, Lien JC, Huang TF. A novel thromboxane receptor antagonist, nstpbp5185, inhibits platelet aggregation and thrombus formation in animal models. Thrombosis and haemostasis 2016; 116: 285-99
• 25 Kim JH, Lee J, Kang S, Moon H, Chung KH, Kim KR. Antiplatelet and Antithrombotic Effects of the Extract of Lindera obtusiloba Leaves. Biomol Ther (Seoul) 2016; 24: 659-664
• 26 Park J, Lee B, Choi H, Kim W, Kim HJ, Cheong H. Antithrombosis activity of protocatechuic and shikimic acids from functional plant Pinus densiflora Sieb. et Zucc needles. J Nat Med 2016; 70: 492-501
• 27 Misra A, Anil Kumar KS, Jain M, Bajaj K, Shandilya S, Srivastava S, Shukla P, Barthwal MK, Dikshit M, Dikshit DK. Synthesis and evaluation of dual antiplatelet activity of bispidine derivatives of N–substituted pyroglutamic acids. Eur J Med Chem 2016; 110: 1-12
• 28 Saito MS, Lourenco AL, Dias LR, Freitas AC, Vitorino MI, Albuquerque MG, Rodrigues CR, Cabral LM, Dias EP, Castro HC, Satlher PC. Antiplatelet pyrazolopyridines derivatives: pharmacological, biochemical and toxicological characterization. J Enzyme Inhib Med Chem 2016; 31: 1591-601
• 29 Lee W, Lee J, Kulkarni R, Kim MA, Hwang JS, Na M, Bae JS. Antithrombotic and antiplatelet activities of small–molecule alkaloids from Scolopendra subspinipes mutilans. Sci Rep 2016; 6: 21956
• 30 Kim TH, Lee KM, Hong ND, Jung YS. Anti-platelet and anti-thrombotic effect of a traditional herbal medicine Kyung-Ok-Ko. J Ethnopharmacol 2016; 178: 172-9